Inactive Instrument

Sawai Pharmaceutical Co., Ltd. Stock price Japan Exchange

Equities

4555

JP3323050009

Pharmaceuticals

Sales 2024 * 202B 1.33B Sales 2025 * 206B 1.36B Capitalization 259B 1.71B
Net income 2024 * 19.42B 128M Net income 2025 * 17.19B 114M EV / Sales 2024 * 1.45 x
Net Debt 2024 * 34.69B 229M Net Debt 2025 * 39.72B 262M EV / Sales 2025 * 1.45 x
P/E ratio 2024 *
13.2 x
P/E ratio 2025 *
15 x
Employees 3,393
Yield 2024 *
2.2%
Yield 2025 *
2.31%
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Jefferies Adjusts Sawai Group’s Price Target to 5,000 Yen From 5,200 Yen, Keeps at Hold MT
Sawai Group Holdings Co., Ltd. Provides Year End Dividend Guidance for the Year Ending March 31, 2024 CI
Sawai Group Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 CI
Bora Pharmaceuticals Co., LTD. agreed to acquire Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd. for approximately $210 million. CI
Neurolief Ltd. announced that it has received funding from Sawai Group Holdings Co., Ltd. CI
Jefferies Adjusts Sawai’s Price Target to 4,500 Yen From 3,500 Yen, Keeps at Hold MT
Sawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 CI
Sawai Group Holdings Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024 CI
Sawai Group Holdings Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year Ending March 31, 2024 CI
Sawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for Period Ending September 2023 and Year Ending March 2024 CI
Sawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the First Half Year Ending September 2023 and Fiscal Year Ending March 31, 2024 CI
Sawai Group Holdings Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023; Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024 CI
Sawai Group Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Sawai Group Holdings Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2023 CI
Sawai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023 CI
More news
Managers TitleAgeSince
Chief Executive Officer 67 21-03-31
President 66 21-03-31
Director/Board Member 64 21-03-31
Members of the board TitleAgeSince
Chief Executive Officer 67 21-03-31
Director/Board Member 55 21-03-31
Director/Board Member 72 21-03-31
More insiders
Sawai Group Holdings Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of medical and over-the-counter drugs. The Company operates in two segments. The Japan segment is engaged in medical and healthcare-related businesses such as manufacture and sale of pharmaceuticals and medical devices, as well as various related businesses. The America segment is engaged in the sale of manufactured pharmaceutical products to wholesale stores in America. The company is also engaged in the research and development of pharmaceutical products.
More about the company
  1. Stock
  2. Equities
  3. Stock Sawai Group Holdings Co., Ltd.
  4. Stock Sawai Pharmaceutical Co., Ltd. - Japan Exchange